Toshifumi Tada, Takashi Kumada, Hiroaki Okushin, Joji Tani, Koichi Takaguchi, Akemi Tsutsui, Hidenori Toyoda, Satoshi Yasuda, Kazufumi Dohmen, Atsushi Hiraoka, Kojiro Michitaka, Kazuhiro Nouso, Kazuya Kariyama, Soo Ryang Kim, Soo Ki Kim, Shinichi Fujioka, Shigeru Mikami, Yuto Watanabe, Tsutomu Tamai, Masanori Atsukawa, Norio Itokawa, Hironori Tanaka, Kunihiko Tsuji, Toru Ishikawa, Michitaka Imai, Ei Itobayashi, Hiroshi Shibata, Noritomo Shimada
INTRODUCTION: The real-world virological efficacy and safety of interferon-free direct-acting antiviral (DAA) therapy with ledipasvir (LDV) plus sofosbuvir (SOF) were assessed in patients who were chronically infected with hepatitis C virus (HCV) genotype 2. METHODS: A total of 126 patients with chronic hepatitis C due to HCV genotype 2 infection who were treated with the LDV/SOF regimen were enrolled. The sustained virological response (SVR) rate and safety were analyzed...
November 3, 2020: Infectious Diseases and Therapy